Herbal drug discovery for the treatment of nonalcoholic fatty liver disease

Few medications are available for meeting the increasing disease burden of nonalcoholic fatty liver disease (NAFLD) and its progressive stage, nonalcoholic steatohepatitis (NASH). Traditional herbal medicines (THM) have been used for centuries to treat indigenous people with various symptoms but without clarified modern-defined disease types and mechanisms. In modern times, NAFLD was defined as a common chronic disease leading to more studies to understand NAFLD/NASH pathology and progression. THM have garnered increased attention for providing therapeutic candidates for treating NAFLD. In this review, a new model called “multiple organs-multiple hits” is proposed to explain mechanisms of NASH progression. Against this proposed model, the effects and mechanisms of the frequently-studied THM-yielded single anti-NAFLD drug candidates and multiple herb medicines are reviewed, among which silymarin and berberine are already under U.S. FDA-sanctioned phase 4 clinical studies. Furthermore, experimental designs for anti-NAFLD drug discovery from THM in treating NAFLD are discussed. The opportunities and challenges of reverse pharmacology and reverse pharmacokinetic concepts-guided strategies for THM modernization and its global recognition to treat NAFLD are highlighted. Increasing mechanistic evidence is being generated to support the beneficial role of THM in treating NAFLD and anti-NAFLD drug discovery.

• Publication year

  2019

• Venue

  Acta Pharmaceutica Sinica B

• Publication date

  2019-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.apsb.2019.11.017PMID 31993304PMCID 6977016
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis.

  2019cited by this paper
• Withaferin A Improves Nonalcoholic Steatohepatitis in Mice

  2019cited by this paper
• 6‐gingerol ameliorates age‐related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction

  2019cited by this paper
• Lipidomic analysis reveals the efficiency of Eclipta prostrata on diet‐induced nonalcoholic fatty liver disease in rats

  2019cited by this paper
• Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation.

  2019cited by this paper
• The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials

  2019cited by this paper
• Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation

  2018cited by this paper
• NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

  2018cited by this paper
• Curcumin Suppresses IL-1β Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome

  2018cited by this paper
• The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

  2018cited by this paper
• The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial.

  2018cited by this paper
• Utilization of traditional and complementary medicine in Indonesia: Results of a national survey in 2014-15.

  2018cited by this paper
• Resveratrol, Metabolic Syndrome, and Gut Microbiota

  2018cited by this paper
• Beneficial Effects of Korean Red Ginseng in the Progression of Non-Alcoholic Steatohepatitis via FABP4 Modulation.

  2018cited by this paper
• Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials

  2018cited by this paper
• Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model.

  2018cited by this paper
• Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway

  2018cited by this paper
• The changing epidemiology of liver diseases in the Asia–Pacific region

  2018cited by this paper
• Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.

  2018cited by this paper
• Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway

  2018cited by this paper
• Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases

  2018cited by this paper
• Curcumin in Liver Diseases: A Systematic Review of the Cellular Mechanisms of Oxidative Stress and Clinical Perspective

  2018cited by this paper
• Mechanisms of NAFLD development and therapeutic strategies

  2018cited by this paper
• No effect of resveratrol on VLDL‐TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease

  2018cited by this paper
• Protective Effects of Chaihu Shugan San (柴胡疏肝散) on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance

  2018cited by this paper
• Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.

  2018cited by this paper
• The gut–liver axis and the intersection with the microbiome

  2018cited by this paper
• Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota.

  2017cited by this paper
• Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis

  2017cited by this paper
• Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications

  2017cited by this paper
• Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance

  2017cited by this paper
• Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver

  2017cited by this paper
• Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials.

  2017cited by this paper
• A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

  2017cited by this paper
• Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation.

  2017cited by this paper
• Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats

  2017cited by this paper
• Jiang Tang Xiao Ke Granule Play an Anti-diabetic Role in Diabetic Mice Pancreatic Tissue by Regulating the mRNAs and MicroRNAs Associated with PI3K-Akt Signaling Pathway

  2017cited by this paper
• Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.

  2017cited by this paper
• Therapies in non‐alcoholic steatohepatitis (NASH)

  2017cited by this paper
• New trends on obesity and NAFLD in Asia.

  2017cited by this paper
• Adipose tissue deficiency of hormone-sensitive lipase causes fatty liver in mice

  2017cited by this paper
• Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis.

  2017cited by this paper
• Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARγ, and suppressing oxidative stress and apoptosis in rats.

  2017cited by this paper
• Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis

  2017cited by this paper
• Curcumin ameliorates liver damage and progression of NASH in NASH‐HCC mouse model possibly by modulating HMGB1‐NF‐&kgr;B translocation

  2017cited by this paper
• Protective effects of glycyrrhizic acid against non‐alcoholic fatty liver disease in mice

  2017cited by this paper
• Berberine ameliorates non-alcoholic steatohepatitis in ApoE−/− mice

  2017cited by this paper
• Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota.

  2017cited by this paper
• Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis

  2017cited by this paper
• Intestinal Farnesoid X Receptor Signaling Modulates Metabolic Disease

  2017cited by this paper
• Silybin inhibits NLRP3 inflammasome assembly through the NAD+/SIRT2 pathway in mice with nonalcoholic fatty liver disease

  2017cited by this paper
• ATF4/ATG5 Signaling in Hypothalamic Proopiomelanocortin Neurons Regulates Fat Mass via Affecting Energy Expenditure

  2017cited by this paper
• Baicalin protects AML-12 cells from lipotoxicity via the suppression of ER stress and TXNIP/NLRP3 inflammasome activation.

  2017cited by this paper
• Cardiovascular and Antiobesity Effects of Resveratrol Mediated through the Gut Microbiota.

  2017cited by this paper
• Understanding the Molecular Mechanisms of the Interplay Between Herbal Medicines and Gut Microbiota

  2017cited by this paper
• Current and future treatment options in non-alcoholic steatohepatitis (NASH)

  2017cited by this paper
• Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c.

  2017cited by this paper
• Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism.

  2017cited by this paper
• Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement.

  2017cited by this paper
• Current and future pharmacological therapies for NAFLD/NASH

  2017cited by this paper
• Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK

  2017cited by this paper
• Anti-Diabetic Effects of Jiang Tang Xiao Ke Granule via PI3K/Akt Signalling Pathway in Type 2 Diabetes KKAy Mice

  2017cited by this paper
• Fat-Specific Sirt6 Ablation Sensitizes Mice to High-Fat Diet–Induced Obesity and Insulin Resistance by Inhibiting Lipolysis

  2017cited by this paper
• Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats.

  2017cited by this paper
• Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells

  2017cited by this paper
• Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway

  2017cited by this paper
• NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

  2017cited by this paper
• Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine

  2017cited by this paper
• Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor

  2016cited by this paper
• Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress

  2016cited by this paper
• Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease.

  2016cited by this paper
• The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis

  2016cited by this paper
• Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD).

  2016cited by this paper
• Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity

  2016cited by this paper
• Innate Immunity and Inflammation in NAFLD/NASH

  2016cited by this paper
• Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver

  2016cited by this paper
• Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease

  2016cited by this paper
• Systematic Understanding of Mechanisms of a Chinese Herbal Formula in Treatment of Metabolic Syndrome by an Integrated Pharmacology Approach

  2016cited by this paper
• Wild ginseng cambial meristematic cells ameliorate hepatic steatosis and mitochondrial dysfunction in high‐fat diet‐fed mice

  2016cited by this paper
• Jiang Tang Xiao Ke Granule, a Classic Chinese Herbal Formula, Improves the Effect of Metformin on Lipid and Glucose Metabolism in Diabetic Mice

  2016cited by this paper
• Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH

  2016cited by this paper
• Possible Integrative Actions of Leptin and Insulin Signaling in the Hypothalamus Targeting Energy Homeostasis

  2016cited by this paper
• Curcumin Represses NLRP3 Inflammasome Activation via TLR4/MyD88/NF-κB and P2X7R Signaling in PMA-Induced Macrophages

  2016cited by this paper
• End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.

  2016cited by this paper
• Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

  2016cited by this paper
• Central nervous system regulation of hepatic lipid and lipoprotein metabolism

  2016cited by this paper
• The role of the gut microbiota in NAFLD

  2016cited by this paper
• Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.

  2016cited by this paper
• Nonalcoholic steatohepatitis (NASH) drugs market

  2016cited by this paper
• Ginger Essential Oil Ameliorates Hepatic Injury and Lipid Accumulation in High Fat Diet-Induced Nonalcoholic Fatty Liver Disease.

  2016cited by this paper
• Meta-analysis of traditional herbal medicine in the treatment of nonalcoholic fatty liver disease.

  2016cited by this paper
• Reverse Pharmacognosy and Reverse Pharmacology; Two Closely Related Approaches for Drug Discovery Development.

  2016cited by this paper
• Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity

  2016cited by this paper
• Treatment of Non‐alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo‐controlled Trial

  2016cited by this paper
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

  2016cited by this paper
• NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling.

  2016cited by this paper
• Intestinal Microbiota and Metabolic Diseases: Pharmacological Implications.

  2016cited by this paper
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

  2016cited by this paper
• Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

  2015cited by this paper
• Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats

  2015cited by this paper

• Acetylshikonin mitigates diet-induced MASLD by targeting PPARγ-mediated metabolic dysfunction

  2026cites this paper
• Emerging Natural Products Against Obesity and MASLD/MASH: Direct Target Discovery and Mechanistic Insights

  2026cites this paper
• Targeting lipophagy and nuclear receptors in metabolic-associated fatty liver disease: insights from traditional Chinese medicine.

  2026cites this paper
• Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment.

  2025cites this paper
• Phytochemicals Targeting Inflammatory Pathways in Alcohol-Induced Liver Disease: A Mechanistic Review

  2025cites this paper
• Preliminary In Silico Evaluation of Potential Therapeutics for Non-Alcoholic Steatohepatitis (NASH) using Molecular Docking and Pharmacokinetics Analysis

  2025cites this paper
• Hepatoprotective Effect of Silymarin Herb in Prevention of Liver Dysfunction Using Pig as Animal Model

  2025cites this paper
• Database mining of ZINC15 natural compounds reveals potential thyroid receptor β agonists for NAFLD management: an in silico study

  2025cites this paper
• Pharmacological properties and therapeutic potential of berberine: a comprehensive review

  2025cites this paper
• First-in-class drug oroxylin A tablets for treating hepatic and gastrointestinal disorders: from preclinical development to clinical research.

  2025cites this paper
• Transcriptomic analysis reveals the mechanisms underlying the differential effects of caffeine, theophylline, and theobromine in regulating hepatic fat accumulation.

  2025cites this paper
• Platycodon grandiflorum Attenuates Non-Alcoholic Fatty Liver Disease in Rats Through Regulating Inflammatory Response via PPARγ and TLR4/NF-κB Signaling Pathway.

  2025cites this paper
• Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach

  2025cites this paper
• Berberine Attenuates Nonalcoholic Hepatic Steatosis by Regulating Lipid Droplet‐Associated Proteins: In Vivo, In Vitro and Molecular Evidence

  2025cites this paper
• Aescin ameliorates alcohol-induced liver injury. A possible implication of ROS / TNF-alpha / p38MAPK / caspase-3 signalling.

  2025cites this paper
• Silymarin and Silybin: Rejuvenating Traditional Remedies with Modern Delivery Strategies

  2025cites this paper
• Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2/TLR4 signaling and pyroptosis.

  2025cites this paper
• Review on Role of Herbs, Spices and Herbal Extracts in Non-alcoholic Steatohepatitis (NASH)

  2025cites this paper
• Limosilactobacillus fermentum role in combination with human mesenchymal stem cell-derived secretome: A novel approach to alleviate inflammation in NASH pathogenesis.

  2025cites this paper
• Ultrafine garlic powder alleviates non-alcoholic steatohepatitis by inhibiting hepatocyte ferroptosis and modulating ERK-dependent oxidative stress

  2025cites this paper
• Novel prolyl endopeptidase inhibitor from Myricaria germanica alleviates steatohepatitis

  2025cites this paper
• Reversal of Grade I NAFLD through yogic intervention.

  2025cites this paper
• Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches

  2025cites this paper
• Hyperoside modulates bile acid and fatty acid metabolism, presenting a potentially promising treatment for non-alcoholic fatty liver disease.

  2025cites this paper
• Fisetinidin chloride ameliorates carbon tetrachloride-induced hepatotoxicity in HepaRG cells

  2025cites this paper
• Therapeutic potential of Glycyrrhiza glabra L. extract and atorvastatin in HFD-induced MAFLD: in vitro and in vivo exploration

  2025cites this paper
• The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.

  2025cites this paper
• Injinoryeong-San Attenuates Metabolic Dysfunction-associated Steatohepatitis via Regulation of YAP/TAZ-Signaling Pathway.

  2025cites this paper
• Oridonin Ameliorates Metabolic‐Dysfunction‐Associated Fatty Liver Disease by Inhibiting PANoptosis via Modulating SIRT2/NLRP3 Pathway

  2025cites this paper
• Exploring the effective substances and mechanisms of action of ChaiHu ShuGan San in treating perimenopausal syndrome based on in vivo exposure profiles and steroid hormone metabolic networks.

  2025cites this paper
• Research progress of TCM intervention in MAFLD based on the AMPK-related signaling pathway

  2025cites this paper
• Taxifolin attenuates liver fibrosis by regulating the phosphorylation of NDRG1 at Thr328 via hepatocyte-stellate cell cross talk

  2025cites this paper
• Acetyl-11-keto-β-boswellic acid alleviates hepatic metabolic dysfunction by inhibiting MGLL activity

  2025cites this paper
• Association of ‘weekend warrior’ and other physical activity patterns with mortality in adults with metabolic dysfunction-associated steatotic liver disease: prospective national cohort study

  2025cites this paper
• The Chinese Herbal TiaoGanXiaoZhi Formula Alleviates the Progression of Metabolic‐Associated Fatty Liver Disease by Regulating the Gut Microbiota

  2025cites this paper
• Advances in research on metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• A Multi-Omics Study Reveals the Active Components and Therapeutic Mechanism of Erhuang Quzhi Formula for Non-Alcoholic Fatty Liver Disease

  2025cites this paper
• Combined analysis of bulk, single-cell RNA sequencing, and spatial transcriptomics reveals the expression patterns of lipid metabolism and ferroptosis in the immune microenvironment of metabolic-associated fatty liver disease.

  2025cites this paper
• Combination of silybin and carvedilol synergistically alleviates liver fibrosis by inhibiting Wnt/β-catenin signaling

  2025cites this paper
• Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives

  2025cites this paper
• Schisanhenol ameliorates non-alcoholic fatty liver disease via inhibiting miR-802 activation of AMPK-mediated modulation of hepatic lipid metabolism

  2024cites this paper
• Liquiritin Alleviates Inflammation in Lipopolysaccharide-Induced Human Corneal Epithelial Cells

  2024cites this paper
• Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD.

  2024cites this paper
• A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways

  2024cites this paper
• Research Progress of Natural Products with the Activity of Anti-nonalcoholic Steatohepatitis.

  2024cites this paper
• Exploration of the Pharmacological Mechanism of Herbal Medicines against Hepatic Disorder: A Systematic Review and Network Pharmacological Analysis

  2024cites this paper
• Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Essential phospholipids impact cytokine secretion and alter lipid-metabolizing enzymes in human hepatocyte cell lines

  2024cites this paper
• A critical assessment of Traditional Chinese Medicine databases as a source for drug discovery

  2024cites this paper
• UPLC-Q-TOF-MS Analysis of Chemical Constituents of the Kadsura coccinea Extract with Effect of Attenuating Lipid Accumulation in Vitro

  2024cites this paper
• Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions.

  2024cites this paper
• The gut-liver axis in fatty liver disease: role played by natural products.

  2024cites this paper
• Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD

  2024cites this paper
• Silybin A from Silybum marianum reprograms lipid metabolism to induce a cell fate-dependent class switch from triglycerides to phospholipids

  2024cites this paper
• Insight into the Regulation of Nrf2/Keap 1 Pathway by Flavonoids as an Approach for Treatment of Liver Diseases: A Review

  2024cites this paper
• Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review

  2024cites this paper
• Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

  2024cites this paper
• The therapeutic effect of alcoholic extract of Fumaria parviflora on high-fat diet-induced nonalcoholic fatty liver in rats: an animal experiment

  2024cites this paper
• Compound Shouwu Jiangzhi Granule regulates triacylglyceride synthesis to alleviate hepatic lipid accumulation.

  2024cites this paper
• Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial.

  2024cites this paper
• Discovery and validation of COX2 as a target of flavonoids in Apocyni Veneti Folium: Implications for the treatment of liver injury.

  2024cites this paper
• Natural products and dietary interventions on liver enzymes: an umbrella review and evidence map

  2024cites this paper
• Sappanone A alleviates metabolic dysfunction-associated steatohepatitis by decreasing hepatocyte lipotoxicity via targeting Mup3 in mice.

  2024cites this paper
• Lactobacillus Casei-fermented Amomum Xanthioides Mitigates non-alcoholic fatty liver disease in a high-fat diet mice model.

  2024cites this paper
• Transcriptotype-Driven Discovery of Apigenin as a Therapy against Cholestatic Liver Fibrosis: Through Inhibition of PANoptosis and Following Type-I Interferon Responses

  2024cites this paper
• Total glucosides of Picrorhizae Rhizome alleviate non-alcoholic steatohepatitis (NASH) by specifically targeting acyl-CoA oxidase 1

  2024cites this paper
• Integrated Lipidomic and transcriptomics to explore the effects of ethyl acetate extract of Herpetospermum pedunculosum on nonalcoholic fatty liver disease in mice.

  2024cites this paper
• Potential of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease: A promising future

  2024cites this paper
• Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research

  2024cites this paper
• Lipid nanosystems for fatty liver therapy and targeted medication delivery a comprehensive review.

  2024cites this paper
• Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction

  2024influential citation
• Evidence-based herbal treatments in liver diseases

  2024cites this paper
• Salidroside may target PPARα to exert preventive and therapeutic activities on NASH

  2024cites this paper
• Zexie-Baizhu Decoction ameliorates non-alcoholic fatty liver disease through gut-adipose tissue crosstalk.

  2024cites this paper
• Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.

  2024cites this paper
• Unveiling the potential of natural compounds in the fight against obesity

  2024cites this paper
• Molecular quantification of fritillariae cirrhosae bulbus and its adulterants

  2024cites this paper
• The potential health benefits and mechanisms of Sesame lignans in age-related diseases

  2024cites this paper
• Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial

  2024cites this paper
• Mechanism investigation of anti-NAFLD of Shugan Yipi Granule based on network pharmacology analysis and experimental verification

  2024cites this paper
• Silymarin targets the FXR protein through microbial metabolite 7-keto-deoxycholic acid to treat MASLD in obese mice.

  2024cites this paper
• Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment

  2024cites this paper
• The Coptidis Rhizoma and Bovis Calculus herb pair attenuates NASH and inhibits the NLRP3 inflammasome activation

  2024cites this paper
• Berberine prevents NAFLD and HCC by modulating metabolic disorders.

  2024cites this paper
• The Glycyrrhiza glabra L. crude extract alleviates lipid accumulation in NAFLD by activating Nrf2 and promoting autophagy

  2024cites this paper
• GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis.

  2024cites this paper
• Comprehensive pharmacological and experimental study of Ginsenoside Re as a potential therapeutic agent for non-alcoholic fatty liver disease.

  2024cites this paper
• Hepatocyte HIF-2α Aggravates NAFLD by Inducing Ferroptosis through Increasing Extracellular Iron.

  2024cites this paper
• Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway

  2023cites this paper
• Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.

  2023cites this paper
• Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress.

  2023cites this paper
• Effect of chin brick tea [Camellia sinensis (L.) Kuntze] on lipid metabolism and inflammation by modulating intestinal flora and bile acids in mice with non-alcoholic fatty liver disease.

  2023cites this paper
• Bean Leaves Ameliorate Lipotoxicity in Fatty Liver Disease

  2023cites this paper
• Three‐dimensional genome structure and function

  2023cites this paper
• Therapeutic potential of alkaloid extract from Codonopsis Radix in alleviating hepatic lipid accumulation: insights into mitochondrial energy metabolism and endoplasmic reticulum stress regulation in NAFLD mice.

  2023cites this paper
• A Mini-Review of Traditional Chinese Medicines on Liver Diseases

  2023cites this paper
• Quantitative proteomics reveals Polygonum perfoliatum L. ameliorates hepatic steatosis by promoting PPARs/CPT1A/CPT2-mediated fatty acid β-oxidation

  2023cites this paper
• PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.

  2023cites this paper
• Aescin can alleviate NAFLD through Keap1-Nrf2 by activating antioxidant and autophagy.

  2023cites this paper
• Yinchenhao Tang alleviates high fat diet induced NAFLD by increasing NR1H4 and APOA1 expression

  2023cites this paper